Intas (Accord) sells US copies of 3 of the blockbuster drugs on this tracker, is approved for 2 more, and has 2 filed or in development. Those brands earned $41.8B in 2025. Of the 70 makers we follow, 12 are lined up to copy more of these drugs.
| Drug | Intas (Accord)'s status | Other makers listed | 2025 brand sales |
|---|---|---|---|
| Stelara ImuldosaBiosimilar · Johnson & Johnson · US LOE 2025 | FDA-approved 10 Oct 2024; launched 18 Aug 2025; interchangeable | 7 on sale · 0 approvedof 7 other makers listed | $6.1B |
| Prolia OsvyrtiBiosimilar · Amgen · US LOE 2025 | FDA-approved 29 Oct 2025; launched 23 Jul 2026; interchangeable | 6 on sale · 3 approvedof 10 other makers listed | $4.4B |
| Xgeva JubereqBiosimilar · Amgen · US LOE 2025 | FDA-approved 29 Oct 2025; launched 23 Jul 2026; interchangeable | 5 on sale · 4 approvedof 10 other makers listed | $2.1B |
| Drug | Intas (Accord)'s status | Other makers listed | 2025 brand sales |
|---|---|---|---|
| Simponi ImmgolisBiosimilar · Johnson & Johnson · US LOE 2026 | FDA-approved 15 May 2026; launch expected in Q4 2026; interchangeable With Bio-Thera |
0 on sale · 0 approvedof 1 other maker listed | $2.7B |
| EliquisGeneric · Bristol Myers Squibb / Pfizer · US LOE 2028 | FDA-approved 28 Jul 2020 | 0 on sale · 2 approvedof 4 other makers listed, plus unnamed filers | $14.4B |
| Drug | Intas (Accord)'s status | Other makers listed | 2025 brand sales |
|---|---|---|---|
| Invega SustennaGeneric · Johnson & Johnson · US LOE 2031 | Filed with the FDA; court ruled for the brand Nov 2025 | 0 on sale · 0 approvedof 3 other makers listed | $3.8B |
| RinvoqGeneric · AbbVie · US LOE 2037 | Filed with the FDA; settled Sep 2025; US entry allowed from Apr 2037. Assuming pediatric exclusivity is granted | 0 on sale · 0 approvedof 4 other makers listed | $8.3B |
Copies not yet on sale, by the earliest year each could reach the US market: a settlement or court date where one is public, otherwise the brand's US exclusivity date. "Now" means that date has passed. Court rulings and new patents can move these.
The brand owner's US sales, as it reports them. They show how fast copies took the market, not Intas (Accord)'s own sales. See the launch tracker →
Each row is a copy Intas (Accord) sells, holds an approval for, has filed, or is developing, for one of the 63 blockbuster drugs this site tracks. It is not Intas (Accord)'s full portfolio. "Other makers listed" counts the other companies on the same drug's list: how many sell a copy and how many more hold an approval. Brand owners and the FDA don't always name every filer, so a list can be incomplete; the drug page says so where we know.
2025 sales are what each brand earned, the size of the market at stake. They are not Intas (Accord)'s sales; several makers usually share a market once copies launch.
Every row is sourced on its drug's page: FDA Orange Book and Purple Book approvals, company releases and filings for launches, and court and company records for settlements. Company facts: Intas.